KETOCONAZOLE HRA (ketoconazole), imidazole

ENDOCRINOLOGY - New medicinal product

Opinions on drugs - Posted on Sep 15 2015

Inclusion

KETOCONAZOLE HRA has Marketing Authorisation in the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.
In retrospective studies with a number of methodological limitations, its efficacy was demonstrated by a reduction in 24-hour urinary free cortisol and in clinical symptoms and comorbidities, in particular arterial hypertension and diabetes.
Because of the known hepatic toxicity of ketoconazole, regular monitoring of liver function and tailoring of the dosage are essential.

Substantial

minor

Therapeutic use

Évaluation des médicaments

All our publications

My account